About Inhibin beta B chain
Inhibin beta B chain (INHBB) is a protein
from Homo sapiens identified by UniProt accession
P09529, 407 residues long.
MolForge cross-references it against 0 known binders and
182 disease associations.
Target properties
| Protein name | Inhibin beta B chain |
| UniProt accession | P09529 |
| Gene | INHBB |
| Organism | Homo sapiens |
| Length | 407 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (182)
Diseases linked to this target (Open Targets).
- prostate carcinoma · score 0.39
- breast carcinoma · score 0.39
- breast size · score 0.32
- puberty onset measurement · score 0.27
- age at menopause · score 0.26
- urate measurement · score 0.26
- low density lipoprotein cholesterol measurement · score 0.25
- testicular hydrocele · score 0.24
- hair colour measurement · score 0.24
- protein measurement · score 0.24
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P09529-F1 | alphafold | PREDICTED | 73.79 | — |
Amino-acid sequence (407 residues)
MDGLPGRALG AACLLLLAAG WLGPEAWGSP TPPPTPAAPP PPPPPGSPGG SQDTCTSCGG FRRPEELGRV DGDFLEAVKR HILSRLQMRG RPNITHAVPK AAMVTALRKL HAGKVREDGR VEIPHLDGHA SPGADGQERV SEIISFAETD GLASSRVRLY FFISNEGNQN LFVVQASLWL YLKLLPYVLE KGSRRKVRVK VYFQEQGHGD RWNMVEKRVD LKRSGWHTFP LTEAIQALFE RGERRLNLDV QCDSCQELAV VPVFVDPGEE SHRPFVVVQA RLGDSRHRIR KRGLECDGRT NLCCRQQFFI DFRLIGWNDW IIAPTGYYGN YCEGSCPAYL AGVPGSASSF HTAVVNQYRM RGLNPGTVNS CCIPTKLSTM SMLYFDDEYN IVKRDVPNMI VEECGCA
Explore Inhibin beta B chain with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets